"GSK acquires efimosfermin alfa from Boston Pharma for $2bn" was originally created and published by Pharmaceutical ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to ...

London: GSK plc has concluded the acquisition of efimosfermin alfa from Boston Pharmaceuticals in a USD 2 billion ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the ...

GSK completes $2 billion acquisition of efimosfermin from Boston Pharmaceuticals: London, UK Wednesday, July 9, 2025, 09:00 Hrs [IST] GSK plc announced the completion of its previ ...

A Cambridge biotech company is preparing to lay off its entire staff of more than 300 after being acquired by another firm.

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

GSK GSK-1.00 % decrease; red down pointing triangle will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs.

Boston Pharmaceuticals licensed the medicine from Novartis in 2020, with GSK now on the hook for success-based milestone payments and tiered royalties to the Swiss drugmaker.

Researchers at Vertex Pharmaceuticals in Boston say a single infusion of stem cell-based treatment could be a permanent solution for insulin. They<a class="excerpt-read-more" href=" More ...

Vertex Pharmaceuticals cuts 125 jobs in Providence, consolidates facilities after ending Type 1 diabetes drug trial. 60 employees to remain. Boston Business Journal Select a City ...